Sell:317.00pBuy:327.50p4.00p
(1.25%)
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. The Company is engaged in providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers a number of technologies for viral vector manufacturing, including a fourth-generation lentiviral vector system (the TetraVecta system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. Its AAV platform, which offers a proprietary plug and play dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.